Spyre Therapeutics Inc. Common Stock (SYRE)

About SYRE

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's d…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

125

Website

spyre.com/

Fundamentals

1-day range

$89.45$93.39

Market cap

$8.35B

P/E (trailing)

—

P/E (forward)

-26.31

EPS (trailing)

$-2.32

Dividend yield

—

Beta

3.05

Avg. volume

1.30M

Forecasts

14 analyst ratings

Spyre Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SYRE

  Spyre Therapeutics Inc. Common Stock

  $90.4

  ▼ 3.43%
  Market cap $8.35BP/E —
  $14.51$110.18
• CYTK

  Cytokinetics Incorporated Common Stock

  $72.17

  ▼ 7.36%
  Market cap $9.51BP/E —
  $35.22$88.31
• COGT

  Cogent Biosciences Inc. Common Stock

  $34.68

  ▼ 6.50%
  Market cap $6.64BP/E —
  $11.6$43.73
• MIRM

  Mirum Pharmaceuticals Inc. Common Stock

  $97.44

  ▼ 2.32%
  Market cap $6.38BP/E —
  $63.23$130
• SMMT

  Summit Therapeutics Inc. Common Stock

  $13.71

  ▼ 4.33%
  Market cap $10.41BP/E —
  $12.07$29.23
• ERAS

  Erasca Inc. Common Stock

  $18.03

  ▼ 7.49%
  Market cap $6.11BP/E —
  $1.33$24.28
• BLTE

  Belite Bio Inc American Depositary Shares

  $151.65

  ▼ 3.42%
  Market cap $6.09BP/E —
  $62.18$200

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Deutsche Bank Maintains Buy on Spyre Therapeutics, Lowers Price Target to $127
  benzinga · 8/26/2026
• Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday
  Benzinga · 8/11/2026
• BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $132
  Benzinga · 8/11/2026
• Spyre Therapeutics Launches New Combination Program SPY772, Comprising Long-Acting Anti-TL1A Antibody SPY072 And Novel Long-Acting Anti-IL-17A/F Antibody In Preclinical Development SPY007
  Benzinga · 8/10/2026
• Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115
  Benzinga · 8/5/2026
• Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130
  Benzinga · 8/5/2026
• Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130
  Benzinga · 8/5/2026
• Spyre Therapeutics Q2 EPS $(0.36) Beats $(0.73) Estimate
  Benzinga · 8/4/2026

• Jeffrey W. Albers · August 7, 2026 · Option Exercise

  5.0K @ $10.39
• Jeffrey W. Albers · August 7, 2026 · Sale

  10.0K @ $104.68
• Jeffrey W. Albers · August 7, 2026 · Sale

  8.0K @ $104.38
• Jeffrey W. Albers · August 7, 2026 · Sale

  5.0K @ $104.47
• Scott L. Burrows · August 3, 2026 · Option Exercise

  7.5K @ $14.5
• Scott L. Burrows · August 3, 2026 · Sale

  100 @ $97.1
• Scott L. Burrows · August 3, 2026 · Sale

  2.3K @ $96.3
• Scott L. Burrows · August 3, 2026 · Sale

  5.1K @ $95.21
• Cameron Turtle · August 3, 2026 · Sale

  16 @ $97.46
• Cameron Turtle · August 3, 2026 · Sale

  1.4K @ $96.82
• Cameron Turtle · August 3, 2026 · Sale

  5.6K @ $95.93
• Cameron Turtle · August 3, 2026 · Sale

  7.2K @ $95.1
• Cameron Turtle · August 3, 2026 · Sale

  800 @ $93.97
• Scott L. Burrows · July 1, 2026 · Option Exercise

  7.5K @ $14.5
• Scott L. Burrows · July 1, 2026 · Sale

  1.7K @ $88.37

Institutional Ownership

March 31, 2026

Total shares held

80.81M

Total value held

$3.99B

Institutional holders

192